Cipher Pharmaceuticals Inc
TSX:CPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cipher Pharmaceuticals Inc
Cash from Operating Activities
Cipher Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Cash from Operating Activities
$30m
|
CAGR 3-Years
26%
|
CAGR 5-Years
32%
|
CAGR 10-Years
10%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Cash from Operating Activities
$1.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
5%
|
CAGR 10-Years
-5%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Cash from Operating Activities
-CA$78.7m
|
CAGR 3-Years
48%
|
CAGR 5-Years
33%
|
CAGR 10-Years
-18%
|
|
|
Cronos Group Inc
TSX:CRON
|
Cash from Operating Activities
$25.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Cash from Operating Activities
-$113.9m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-117%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Cash from Operating Activities
CA$69m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
25%
|
|
Cipher Pharmaceuticals Inc
Glance View
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.
See Also
What is Cipher Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
30m
USD
Based on the financial report for Sep 30, 2025, Cipher Pharmaceuticals Inc's Cash from Operating Activities amounts to 30m USD.
What is Cipher Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
10%
Over the last year, the Cash from Operating Activities growth was 124%. The average annual Cash from Operating Activities growth rates for Cipher Pharmaceuticals Inc have been 26% over the past three years , 32% over the past five years , and 10% over the past ten years .
